News & Updates

The antiviral molnupiravir confers continued but modest benefits in terms of reducing COVID-19–related symptoms up to 6 months after the index infection in a vaccinated population, according to a secondary analysis of the PANORAMIC trial.

A recent study has found that laughing can be as effective as artificial tears (ie, 0.1% sodium hyaluronic acid eye drop) in relieving ocular surface discomfort in patients with dry eye disease (DED) with limited corneal staining.

The combination of re-cellularization via electroporation therapy (ReCET) plus semaglutide appears to improve glucose control and metabolic health and eliminate the need for insulin therapy in most patients with type 2 diabetes (T2D), with the effects maintained up to 2 years, according to the follow-up data from the single-arm, dose-finding, first-in-human EMINENT trial.

In Singapore, influenza and pneumococcal vaccination coverage remains stubbornly low. Results of two separate analysis of a cross-sectional survey shed light on this concerning trend, highlighting the roles of vaccine knowledge and attitude, healthcare professionals, and social support in influencing vaccination decisions.

The novel plant-based polyphenol-rich compound, TOTUM-63, helps keep the lid on fasting plasma glucose (FPG) and other measures of glucose dysregulation in people with prediabetes and early type 2 diabetes (T2D), according to the pivotal phase II/III REVERSE-IT study.

Treatment with depemokimab results in a substantial decrease in exacerbations, with an acceptable safety profile, among severe asthma patients with an eosinophilic phenotype, results of the SWIFT-1 and 2 studies have shown.

The time of steroids as the treatment of choice for asthma and chronic obstructive pulmonary disease (COPD) exacerbations appears to be nearing its end with the arrival of a new monoclonal antibody therapy, according to the results of the ABRA study.